Berirab P

Berirab P

rabies immunoglobulin

Manufacturer:

CSL Behring

Distributor:

Zuellig
Concise Prescribing Info
Contents
Human rabies Ig
Indications/Uses
Post-exposure prophylaxis of rabies infection after exposure to scratches, bites or other injuries caused by a suspected rabid animal; mucous membrane contamination w/ infectious tissue or saliva of a suspected rabid animal; contact of mucous membranes or newly skin injury w/ rabies live attenuated vaccine eg, vaccination baits.
Dosage/Direction for Use
Special Precautions
Do not administer into a blood vessel. Anaphylactic reactions in IgA deficient patients. Observe patient for at least 20 min after administration.
Adverse Reactions
Rarely, allergic reactions including BP fall, dyspnoea, cutaneous reactions; generalized reactions eg, chills, fever, headache, malaise, nausea, vomiting, arthralgia & moderate back pain; CV reactions if inadvertently injected IV. Local reactions (local pain at the inj site, tenderness or swelling).
Drug Interactions
May impair the efficacy of live attenuated virus vaccines eg, measles, rubella, mumps & varicella vaccines for a period of up to 3 mth. May result in misleading +ve test results in serological testing due to transitory rise of passively transferred Abs after inj. May interfere w/ some serological tests for red cell allo-Abs (eg, Coombs' test).
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J06BB05 - rabies immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Presentation/Packing
Form
Berirab P vaccine (inj) 300 IU/2 mL
Packing/Price
2 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in